NICE
ABPI slams NICE International
August 20, 2012Sales and Marketing ABPI, NICE, NICE International, Romania, hta
The ABPI has expressed concerns over the remit of NICE International and its affect on global markets. NICE International is …
Xgeva gains NICE recommendation for bone metastasis
August 17, 2012Sales and Marketing Amgen, NICE, Xgeva, bone metastatis
NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. …
NICE still minded not to recommend Zelboraf
August 9, 2012Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf
NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …
Nicholson to end NHS black listing of drugs
August 9, 2012Sales and Marketing IHW, NHS, NICE, Sir David Nicholson, formulary
The chief executive of the NHS is looking to stamp out black listing of NICE-approved medicines. In a letter to …
GSK’s Votrient gains new licence
August 8, 2012Sales and Marketing GSK, NICE, Votrient, soft cell sarcoma
GlaxoSmithKline has gained a new European licence for its cancer pill Votrient adding to its renal cell carcinoma licence. The …
Sue NHS to ensure access to drugs, says NICE chief
August 6, 2012Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology
The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …
ABPI outlines vision for drug pricing reform
August 3, 2012Sales and Marketing ABPI, NICE, PPRS, VBP, Whitehead, value-based pricing
The ABPI has set out what it wants to see from the new drug pricing system in the UK. Negotiations …
NICE yes for Xarelto to treat blood clots
July 25, 2012Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto
NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …
NICE to assess high cost drugs for rare conditions
July 24, 2012Sales and Marketing AGNSS, NHS, NICE, Rawlins, rare conditions
NICE is to be responsible next year for assessing high cost drugs for people with rare medical conditions as part …
NICE no for Avastin in breast cancer
July 6, 2012Sales and Marketing NICE, Roche, avastin, breast cancer, rejection
NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …
Astellas submits new prostate cancer drug to EMA
June 28, 2012Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide
Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
MPs find NHS bodies still blocking treatments
June 25, 2012Sales and Marketing CCGs, MPs, NHS, NICE, PCTs, Pfizer, viagra
The Labour party has uncovered new restrictions to treatments and drugs in the NHS, which it says is hurting patients …
The European Medicines Group: focused on UK market access
June 25, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, EMG, NICE, VBP, market access
Maintaining a dialogue with government, NHS organisations and other stakeholder groups is essential for pharma companies in the UK, and …
Janssen looks to broaden Zytiga licence
June 18, 2012Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate
Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …
